In renal cell carcinoma, combined low levels of VEGF and Apelin in sunitinib‐treated patient serum correlated with a 6‐fold longer progression‐free survival compared to patients with high levels of both VEGF and Apelin. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.